>
Switch to:

Illumina Liabilities-to-Assets

: 0.29 (As of Mar. 2022)
View and export this data going back to 2000. Start your Free Trial

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. Illumina's Total Liabilities for the quarter that ended in Mar. 2022 was $4,379 Mil. Illumina's Total Assets for the quarter that ended in Mar. 2022 was $15,274 Mil. Therefore, Illumina's Liabilities-to-Assets Ratio for the quarter that ended in Mar. 2022 was 0.29.


Illumina Liabilities-to-Assets Historical Data

The historical data trend for Illumina's Liabilities-to-Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Illumina Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Liabilities-to-Assets
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.48 0.45 0.37 0.38 0.29

Illumina Quarterly Data
Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22
Liabilities-to-Assets Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.44 0.40 0.30 0.29 0.29

Competitive Comparison

For the Diagnostics & Research subindustry, Illumina's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Illumina Liabilities-to-Assets Distribution

For the Medical Diagnostics & Research industry and Healthcare sector, Illumina's Liabilities-to-Assets distribution charts can be found below:

* The bar in red indicates where Illumina's Liabilities-to-Assets falls into.



Illumina Liabilities-to-Assets Calculation

Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.

Illumina's Liabilities-to-Assets Ratio for the fiscal year that ended in Dec. 2021 is calculated as:

Liabilities-to-Assets (A: Dec. 2021 )=Total Liabilities/Total Assets
=4477/15217
=0.29

Illumina's Liabilities-to-Assets Ratio for the quarter that ended in Mar. 2022 is calculated as

Liabilities-to-Assets (Q: Mar. 2022 )=Total Liabilities/Total Assets
=4379/15274
=0.29

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Illumina  (NAS:ILMN) Liabilities-to-Assets Explanation

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.


Illumina Liabilities-to-Assets Related Terms

Thank you for viewing the detailed overview of Illumina's Liabilities-to-Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Illumina Business Description

Illumina logo
Industry
Address
5200 Illumina Way, San Diego, CA, USA, 92122
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates revenue from sequencing tools and dedicated consumables (76% of 2020 sales). Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications. Services account for 16% of sales and include basic maintenance services, clinical lab applications (such as noninvasive prenatal, oncology, and rare-disease screening), and whole genome sequencing.
Executives
Flatley Jay T director 9885 TOWNE CENTRE DR SAN DIEGO CA 92121
Tousi Susan H officer: SVP Product Development 5200 ILLUMINA WAY SAN DIEGO CA 92122
Reeves Kathryne Gambrell officer: SVP, Chief Marketing Officer 5200 ILLUMINA WAY SAN DIEGO CA 92122
Goswami Joydeep officer: SVP Corp Business Development SUMITOMO FUDOSAN MITA TWIN BLDG EAST WING 4-2-8 SHIBAURA MINATO-KU TOKYO M0 1080023
Dadswell Charles officer: SVP & General Counsel 5200 ILLUMINA WAY SAN DIEGO CA 92122
Desouza Francis A director, officer: President and CEO 350 ELLIS STREET MOUNTAIN VIEW CA 94043
Van Oene Mark officer: SVP Chief Commercial Officer 5200 ILLUMINA WAY SAN DIEGO CA 92122
Ragusa Robert P officer: SVP, Global Quality & Ops PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"> Ownership Information: RAGUSA ROBERT P a.header:link {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:visited {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:hover {color: #191970;}
Mcginnis Karen K officer: VP, Chief Accounting Officer INSIGHT ENTERPRISES INC 1305 WEST AUTO DRIVE TEMPE AZ 85284
Hoyt Aimee L officer: SVP, Chief People Officer 5200 ILLUMINA WAY SAN DIEGO CA 92122
Ronaghi Mostafa officer: SVP, Entrepreneurial Devlopmt 9885 TOWNE CENTRE DRIVE SAN DIEGO CA 92121
Aravanis Alexander officer: SVP, Chief Technology Officer 5200 ILLUMINA WAY SAN DIEGO CA 92122
Siegel Susan E director 3000 SAND HILL ROAD BLDG 3 STE 290 MENLO PARK CA 94025
Thompson John Wendell director C/O MICROSOFT CORPORATION ONE MICROSOFT WAY REDMOND WA 98053
Epstein Robert S director PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"> Ownership Information: EPSTEIN ROBERT S a.header:link {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:visited {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:hover {color: #191970;}

Illumina Headlines

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)